{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:16:23Z","timestamp":1756383383319,"version":"3.44.0"},"reference-count":27,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:p>Tadalafil is a phosphodiesterase type-5 (PDE5) inhibitor licensed for the treatment of erectile dysfunction (ED) in adult males (Cialis\u2014Lilly) and for the management of pulmonary arterial hypertension (Adcirca\u2014Lilly).<jats:sup>1<\/jats:sup> The 5mg tablet was licensed in November 2012 for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult males (Cialis 5mg\u2014Lilly).<jats:sup>2<\/jats:sup> In this article, we consider the evidence for tadalafil and how its use fits with current management strategies for BPH.<\/jats:p>","DOI":"10.1136\/dtb.2013.8.0199","type":"journal-article","created":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T09:53:51Z","timestamp":1376560431000},"page":"93-96","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Tadalafil for benign prostatic hyperplasia"],"prefix":"10.1136","volume":"51","member":"239","published-online":{"date-parts":[[2013,8,15]]},"reference":[{"key":"2025082723165191000_51.8.93.1","unstructured":"Committee for Medicinal Products for Human Use (CHMP), 2012. Assessment report. Cialis: tadalafil [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000436\/WC500137787.pdf [Accessed 24 July 2013]."},{"key":"2025082723165191000_51.8.93.2","unstructured":"Cialis 2.5mg, 5mg, 10mg, 20mg film-coated tablets. Summary of Product Characteristics, UK. Eli Lilly and Company Limited, March 2013."},{"key":"2025082723165191000_51.8.93.3","unstructured":"National Institute for Health and Care Excellence Clinical Knowledge Summaries, 2013. LUTS in men, age-related (prostatism) [online]. Available: http:\/\/cks.nice.org.uk\/luts-in-men-age-related-prostatism#!backgroundsub [Accessed 24 July 2013]."},{"key":"2025082723165191000_51.8.93.4","unstructured":"National Clinical Guideline Centre, 2010. Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. NICE clinical guideline 97 [online]. Available: http:\/\/www.nice.org.uk\/nicemedia\/live\/12984\/48554\/48554.pdf [Accessed 24 July 2013]."},{"key":"2025082723165191000_51.8.93.5","doi-asserted-by":"crossref","unstructured":"Logie J Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU Int 2005; 95: 557\u201362.","DOI":"10.1111\/j.1464-410X.2005.05339.x"},{"key":"2025082723165191000_51.8.93.6","doi-asserted-by":"crossref","unstructured":"Verhamme KM Triumph Pan European Expert Panel . Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project. Eur Urol 2002; 42: 323\u20138.","DOI":"10.1016\/S0302-2838(02)00354-8"},{"key":"2025082723165191000_51.8.93.7","doi-asserted-by":"crossref","unstructured":"Andersson KE Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011; 30: 292\u2013301.","DOI":"10.1002\/nau.20999"},{"key":"2025082723165191000_51.8.93.8","doi-asserted-by":"crossref","unstructured":"Mouli S PDE5 inhibitors for LUTS. Prostate Cancer Prostatic Dis 2009; 12: 316\u201324.","DOI":"10.1038\/pcan.2009.27"},{"key":"2025082723165191000_51.8.93.9","doi-asserted-by":"crossref","unstructured":"Gonzalez RR Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Expert Opin Drug Metab Toxicol 2006; 2: 609\u201317.","DOI":"10.1517\/17425255.2.4.609"},{"key":"2025082723165191000_51.8.93.10","doi-asserted-by":"crossref","unstructured":"Myatt A Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction. Therapy 2008; 5: 355\u201365.","DOI":"10.2217\/14750708.5.3.355"},{"key":"2025082723165191000_51.8.93.11","doi-asserted-by":"crossref","unstructured":"Barry MJ Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 1770\u20134.","DOI":"10.1016\/S0022-5347(01)66780-6"},{"key":"2025082723165191000_51.8.93.12","doi-asserted-by":"crossref","unstructured":"Rosen RC Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol 2011; 60: 1010\u20136.","DOI":"10.1016\/j.eururo.2011.07.053"},{"key":"2025082723165191000_51.8.93.13","doi-asserted-by":"crossref","unstructured":"Laydner HK Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. BJU Int 2011; 107: 1104\u20139.","DOI":"10.1111\/j.1464-410X.2010.09698.x"},{"key":"2025082723165191000_51.8.93.14","doi-asserted-by":"crossref","unstructured":"Roehrborn CG Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228\u201334.","DOI":"10.1016\/j.juro.2008.06.079"},{"key":"2025082723165191000_51.8.93.15","doi-asserted-by":"crossref","unstructured":"Egerdie RB Tadalafil 2.5 or 5mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012; 9: 271\u201381.","DOI":"10.1111\/j.1743-6109.2011.02504.x"},{"key":"2025082723165191000_51.8.93.16","doi-asserted-by":"crossref","unstructured":"Porst H Efficacy and safety of tadalafil once daily in the treatment of men with lowere urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized double-blind, placebo-controlled trial. Eur Urol 2011; 60: 1105\u201313.","DOI":"10.1016\/j.eururo.2011.08.005"},{"key":"2025082723165191000_51.8.93.17","doi-asserted-by":"crossref","unstructured":"Oelke Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled trial. Eur Urol 2012; 61: 917\u201325.","DOI":"10.1016\/j.eururo.2012.01.013"},{"key":"2025082723165191000_51.8.93.18","doi-asserted-by":"crossref","unstructured":"Donatucci CF Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int 2011; 107: 1110\u20136.","DOI":"10.1111\/j.1464-410X.2010.09687.x"},{"key":"2025082723165191000_51.8.93.19","doi-asserted-by":"crossref","unstructured":"Gomelsky A Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH. Curr Urol Rep 2010; 11: 254\u201360.","DOI":"10.1007\/s11934-010-0122-8"},{"key":"2025082723165191000_51.8.93.20","doi-asserted-by":"crossref","unstructured":"Dmochowski R Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 2013; 189: S135\u201340.","DOI":"10.1016\/j.juro.2012.11.025"},{"key":"2025082723165191000_51.8.93.21","unstructured":"National Institute for Health and Clinical Excellence, 2013. Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) [online]. Available: http:\/\/publications.nice.org.uk\/tadalafil-for-the-treatment-of-symptoms-associated-with-benign-prostatic-hyperplasia-terminated-ta273 [Accessed 24 July 2013]."},{"key":"2025082723165191000_51.8.93.22","unstructured":"Scottish Medicines Consortium, 2012. Statement of Advice: tadalafil (Cialis\u00ae) 5mg film coated tablets [online]. Available: http:\/\/www.scottishmedicines.org.uk\/files\/advice\/tadalafil_Cialis_Non_Submission_FINAL_December_2012_for_website.pdf [Accessed 24 July 2013]."},{"key":"2025082723165191000_51.8.93.23","unstructured":"All Wales Medicines Strategy Group, 2013. Tadalafil for the treatment of the signs and symptoms of benign prostatic hyperplasia in adult males [online]. Available: http:\/\/www.awmsg.org\/awmsgonline\/app\/appraisalinfo\/618 [Accessed 24 July 2013]."},{"key":"2025082723165191000_51.8.93.24","unstructured":"National Institute for Health and Care Excellence, 2013. ESNM18: Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil [online]. Available: http:\/\/publications.nice.org.uk\/esnm18-lower-urinary-tract-symptoms-secondary-to-benign-prostatic-hyperplasia-tadalafil-esnm18\/ [Accessed 24 July 2013]."},{"key":"2025082723165191000_51.8.93.25","unstructured":"NHS Business Services Authority, 2013. National Health Service England and Wales Electronic Drug Tariff [online]. Available: http:\/\/www.ppa.org.uk\/edt\/July_2013\/mindex.htm [Accessed 24 July 2013]."},{"key":"2025082723165191000_51.8.93.26","unstructured":"ISD Scotland, 2013. Scottish Drug Tariff [online]. Available: http:\/\/www.isdscotland.org\/Health-Topics\/Prescribing-and-Medicines\/Scottish-Drug-Tariff\/ [Accessed 24 July 2013]."},{"key":"2025082723165191000_51.8.93.27","unstructured":"HSC Business Services Organisation, 2013. Drug Tariff [online]. Available: http:\/\/www.hscbusiness.hscni.net\/services\/2034.htm [Accessed 24 July 2013]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2013.8.0199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:17:00Z","timestamp":1756361820000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2013.8.0199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,15]]},"published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1136\/dtb.2013.8.0199"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2013.8.0199","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}